

เอกสารอ้างอิง

References MD arylamide

- [1] World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response.
- [2] A. Quémard, J.C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W.R. Jacobs Jr., J.S. Blanchard, Enzymatic characterization of the target for isoniazid in *Mycobacterium tuberculosis*, *Biochemistry* 34 (1995) 8235-8241.
- [3] J.W. Campbell, J.E. Cronan Jr., Bacterial fatty acid biosynthesis: Targets for antibacterial drug discovery, *Annu. Rev. Microbiol.* 55 (2001) 305-332.
- [4] R.J. Heath, C.O. Rock, Fatty acid biosynthesis as a target for novel antibacterials, *Curr. Opin. Invest. Drugs* 5 (2004) 146-153.
- [5] S.W. White, J. Zheng, Y.M. Zhang, C.O. Rock, The structural biology of type II fatty acid biosynthesis, *Annu. Rev. Biochem.* 74 (2005) 791-831.
- [6] Y.M. Zhang, Y.J. Lu, C.O. Rock, The reductase steps of the type II fatty acid synthase as antimicrobial targets, *Lipids* 39 (2004) 1055-1060.
- [7] L. Wen, J.N. Chmielowski, K.C. Bohn, J.K. Huang, Y.N. Timsina, P. Kodali, A.K. Pathak, Functional expression of *Francisella tularensis* FabH and FabI, potential antibacterial targets, *Protein Expr. Purif.* 65 (2009) 83-91.
- [8] H.T. Wright, K.A. Reynolds, Antibacterial targets in fatty acid biosynthesis, *Curr. Opin. Microbiol.* 10 (2007) 447-453.
- [9] D.A. Rozwarski, G.A. Grant, D.H. Barton, W.R. Jacobs Jr., J.C. Sacchettini, Modification of the NADH of the isoniazid target (InhA) from *Mycobacterium tuberculosis*, *Science* 279 (1998) 98-102.
- [10] C. Vilchèze, F. Wang, M. Arai, M.H. Hazbón, R. Colangeli, L. Kremer, T.R. Weisbrod, D. Alland, J.C. Sacchettini, W.R. Jacobs Jr., Transfer of a point mutation in *Mycobacterium tuberculosis inhA* resolves the target of isoniazid, *Nat. Med.* 12 (2006) 1027-1029.
- [11] A. Dessen, A. Quémard, J.S. Blanchard, W.R. Jacobs Jr., J.C. Sacchettini, Crystal structure and function of the isoniazid target of *Mycobacterium tuberculosis*, *Science* 267 (1995) 1638-1641.

- [12] B. Lei, C.J. Wei, S.C. Tu, Action mechanism of antitubercular isoniazid. Activation by *Mycobacterium tuberculosis* KatG, isolation, and characterization of inha inhibitor, *J. Biol. Chem.* 275 (2000) 2520–2526.
- [13] K. Johnsson, D.S. King, P.G. Schultz, Studies on the Mechanism of Action of Isoniazid and Ethionamide in the Chemotherapy of Tuberculosis, *J. Am. Chem. Soc.* 117 (1995) 5009–5010.
- [14] A. Que´mard, A. Dessen, M. Sugantino, W.R. Jacobs Jr., J.C. Sacchettini, J.S. Blanchard, Binding of Catalase-Peroxidase-Activated Isoniazid to Wild-Type and Mutant *Mycobacterium tuberculosis* Enoyl-ACP Reductases, *J. Am. Chem. Soc.* 118 (1996) 1561-1562.
- [15] B. Saint-Joanis, H. Souchon, M. Wilming, K. Johnsson, P.M. Alzari, S.T. Cole, Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/oxidase, KatG, from *Mycobacterium tuberculosis*, *Biochem. J.* 338 (1999) 753-760.
- [16] X. Zhao, H. Yu, S. Yu, F. Wang, J.C. Sacchettini, R.S. Magliozzo, Hydrogen Peroxide-Mediated Isoniazid Activation Catalyzed by *Mycobacterium tuberculosis* Catalase-Peroxidase (KatG) and Its S315T Mutant, *Biochemistry* 45 (2006) 4131-4140.
- [17] C. Metcalfe, I.K. Macdonald, E.J. Murphy, K.A. Brown, E.L. Raven, P.C. Moody, The tuberculosis prodrug isoniazid bound to activating peroxidases, *J. Biol. Chem.* 283 (2008) 6193-6200.
- [18] B.K. Sinha, Enzymatic Activation of Hydrazine Derivatives, *J. Biol. Chem.* 258 (1983) 796-801.
- [19] M. Nguyen, C. Claparols, J. Bernadou, B. Meunier, A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts, *ChemBioChem* 2 (2001) 877-883.
- [20] B. Heym, Y. Zhang, S. Poulet, D. Young, S.T. Cole, Characterization of the katG gene encoding a catalase-oxidase required for the isoniazid susceptibility of *Mycobacterium tuberculosis*, *J. Bacteriol.* 175 (1993) 4255-4259.
- [21] K. Johnsson, P.G. Schultz, Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from *Mycobacterium tuberculosis*, *J. Am. Chem. Soc.* 116 (1994) 7425–7426.
- [22] G.S. Timmins, V. Deretic, Mechanisms of action of isoniazid, *Mol. Microbiol.* 62 (2006) 1220-1227.

- [23]K. Johnsson, W.A. Froland, P.G. Schultz, Overexpression, purification, and characterization of the catalase-peroxidase KatG from *Mycobacterium tuberculosis*, *J. Biol. Chem.* 272 (1997) 2834-2840.
- [24]C. Vilcheze, H. R. Morbidoni, T. R. Weisbrod, H. Iwamoto, M. Kuo, J.C. Sacchettini, W.R. Jacobs Jr., Inactivation of the *inhA*-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASII end products and cell lysis of *Mycobacterium smegmatis*, *J. Bacteriol.* 182 (2000) 4059–4067.
- [25]A.S. Piatek, A. Telenti, M.R. Murray, H. El-Hajj, W.R. Jacobs Jr., F.R. Kramer, D. Alland, Genotypic analysis of *Mycobacterium tuberculosis* in two distinct populations using molecular beacons: implications for rapid susceptibility testing, *Antimicrob. Agents Chemother.* 44 (2000) 103–110.
- [26]R.A. Slayden, C.E. Barry 3rd, The genetics and biochemistry of isoniazid resistance in *Mycobacterium tuberculosis*, *Microbes. Infect.* 2 (2000) 659–669.
- [27]M.J. Torres, A. Criado, J.C. Palomares, J. Aznar, Use of real-time PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in *Mycobacterium tuberculosis*, *J. Clin. Microbiol.* 38 (2000) 3194–3199.
- [28]Y. Zhang, B. Heym, B. Allen, D. Young, S. Cole, The catalaseperoxidase gene and isoniazid resistance of *Mycobacterium tuberculosis*, *Nature* 358 (1992) 591–593.
- [29] J.S. Oliveira, J.H. Pereira, F. Canduri, N.C. Rodrigues, O.N. de Souza, W.F. de Azevedo Jr., L.A. Basso, D.S. Santos. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from *Mycobacterium tuberculosis*, *J. Mol. Biol.* 359 (2006) 646-666.
- [30] M.R. Marques, J.H. Pereira, J.S. Oliveira, L.A. Basso, D.S. Santos, W.F. de Azevedo Jr., M.S. Palma. The inhibition of 5-enolpyruvylshikimate-3-phosphate synthase as a model for development of novel antimicrobials, *Curr. Drug Targets* 8 (2007) 445-457.
- [31]A.I. De La Iglesia, H.R. Morbidoni, Mechanisms of action of and resistance to rifampicin and isoniazid in *Mycobacterium tuberculosis*: new information on old friends, *Rev. Argent Microbiol.* 38 (2006) 97-109.
- [32]A. Banerjee, E. Dubnau, A. Quemard, V. Balasubramanian, K.S. Um, T. Wilson, D. Collins, G. de Lisle, W.R. Jacobs Jr., *inhA*, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*, *Science* 263 (1994) 227–230.

- [33] J.S. Freundlich, F. Wang, C. Vilchèze, G. Gulten, R. Langley, G.A. Schiehsler, D.P. Jacobus, W.R. Jacobs Jr., J.C. Sacchettini, Triclosan derivatives: Towards potent inhibitors of drug-sensitive and drug-resistant *Mycobacterium tuberculosis*, *Chem. Med. Chem.* 4 (2009) 241-248.
- [34] C.W. am Ende, S.E. Knudson, N. Liu, J. Childs, T.J. Sullivan, M. Boyne, H. Xu, Y. Gegina, D.L. Knudson, F. Johnson, C.A. Peloquin, R.A. Slayden, P.J. Tonge, Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors, *Bioorg. Med. Chem. Lett.* 18 (2008) 3029-3033.
- [35] M.E. Boyne, T.J. Sullivan, C.W. am Ende, H. Lu, V. Gruppo, D. Heaslip, A.G. Amin, D. Chatterjee, A. Lenaerts, P.J. Tonge, R.A. Slayden, Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against *Mycobacterium tuberculosis*: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors, *Antimicrob. Agents Chemother.* 51 (2007) 3562-3567.
- [36] P.J. Tonge, C. Kisker, R.A. Slayden, Development of modern InhA inhibitors to combat drug resistant strains of *Mycobacterium tuberculosis*, *Curr. Top. Med. Chem.* 7 (2007) 489-498.
- [37] X. He, A. Alian, R. Stroud, P.R. Ortiz de Montellano, Pyrrolidine Carboxamides as a Novel Class of Inhibitors of Enoyl Acyl Carrier Protein Reductase from *Mycobacterium tuberculosis*, *J. Med. Chem.* 49 (2006) 6308-6323.
- [38] X. He, A. Alian, P.R. Ortiz de Montellano, Inhibition of the *Mycobacterium tuberculosis* enoyl acyl carrier protein reductase InhA by arylamides, *Bioorg. Med. Chem.* 15 (2007) 6649-6658.
- [39] S. Alcaro, A. Artese, F. Ceccherini-Silberstein, F. Ortuso, C.F. Perno, T. Sing, V. Svicher, Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance, *J. Chem. Inf. Model.* 49 (2009) 1751-1761.
- [40] H.A. Wahab, Y.S. Choong, P. Ibrahim, A. Sadikun, T. Scior, Elucidating isoniazid resistance using molecular modeling, *J. Chem. Inf. Model.* 49 (2009) 97-107.
- [41] A. Ivetac, J.A. McCammon, Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations, *J. Mol. Biol.* 388 (2009) 644-658.
- [42] J.J. Tan, R. Kong, C.X. Wang, W.Z. Chen, Molecular dynamics simulation on the complexes of N-terminal region of HIV-1 gp41 and its C-peptide inhibitors, *Theochem* 682 (2004) 9-15.

- [43] S. Weerasinghe, R. Samantha Dassanayake, Simulation of structural and functional properties of mevalonate diphosphate decarboxylase (MVD), *J. Mol. Model.* 16 (2010) 489-498.
- [44] V. Nukoolkarn, V.S. Lee, M. Malaisree, O. Aruksakulwong, S. Hannongbua, Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors, *J. Theor. Biol.* 254 (2008) 861-786.
- [45] M. Liu, X.J. Cong, P. Li, J.J. Tan, W.Z. Chen, C.X. Wang, Study on the inhibitory mechanism and binding mode of the hydroxycoumarin compound NSC158393 to HIV-1 integrase by molecular modeling, *Biopolymers* 91 (2009) 700-709.
- [46] Y. Zhao, W. Li, J. Zeng, G. Liu, Y. Tang, Insights into the interactions between HIV-1 integrase and human LEDGF/p75 by molecular dynamics simulation and free energy calculation, *Proteins* 72 (2008) 635-645.
- [47] S. Han, Molecular dynamics simulations of thioredoxin with S-glutathiolated cysteine-73, *Biochem. Biophys. Res. Commun.* 362 (2007) 532-537.
- [48] D.A. Rozwarski, C. Vilchèze, M. Sugantino, R. Bittman, J.C. Sacchettini, Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD⁺ and a C16 fatty acyl substrate, *J. Biol. Chem.* 274 (1999) 15582-15589.
- [49] G.M. Morris, D.S. Goodshell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, A.J. Olson, Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function, *J. Comput. Chem.* 19 (1998) 1639-1662.
- [50] D. van der Spoel, E. Lindahl, B. Hess, G. Groenhof, A.E. Mark, H.J.C. Berendsen, GROMACS: fast, flexible and free, *J. Comp. Chem.* 26 (2005) 1701-1719.
- [51] H.J.C. Berendsen, D. van der Spoel, R. van Drunen, GROMACS: a message-passing parallel molecular dynamics implementation, *Comp. Phys. Comm.* 91 (1995) 43-56.
- [52] E. Lindahl, B. Hess, D. van der Spoel, Package for molecular simulation and trajectory analysis, *J. Mol. Mod.* 7 (2001) 306-317.
- [53] W.R.P. Scott, P.H. Hunenberger, I.G. Tironi, A.E. Mark, S.R. Billeter, J. Fennen, A.E. Torda, T. Huber, P. Kruger, W.F. van Gunsteren, The GROMOS biomolecular simulation program package, *J. Phys. Chem. A* 103 (1999) 3596-3607.
- [54] J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, D.A. Case, Development and testing of a general AMBER force field, *J. Comput. Chem.* 25 (2004) 1157-1174.
- [55] H.J.C. Berendsen, J.R. Grigera, T.P. Straatsma, The missing term in effective pair potentials, *J. Phys. Chem.* 91 (1987) 6269-6271.

- [56] B. Hess, H. Bekker, H.J.C. Berendsen, J. Fraaije, LINCS: a linear constraint solver for molecular simulations, *J. Comput. Chem.* 18 (1997) 1463–1472.
- [57] T. Darden, D. York, L. Pedersen, Particle mesh Ewald—an N·Log(N) method for Ewald sums in large systems, *J. Chem. Phys.* 98 (1993) 10089–10092.
- [58] J. Aqvist, C. Medina, J.E. Samuelsson, A new method for predicting binding affinity in computer-aided drug design, *Protein Eng.* 7 (1994) 385–391.
- [59] M.R. Kuo, H.R. Morbidoni, D. Alland, S.F. Sneddon, B.B. Gourlie, M.M. Staveski, M. Leonard, J.S. Gregory, A.D. Janjigian, C. Yee, J.M. Musser, B. Kreiswirth, H. Iwamoto, R. Perozzo, W.R. Jacobs Jr, J.C. Sacchettini, D.A. Fidock, Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data, *J. Biol. Chem.* 278 (2003) 20851–20859.
- [60] C.W. am Ende, S.E. Knudson, N. Liu, J. Childs, T.J. Sullivan, M. Boyne, H. Xu, Y. Gegina, D.L. Knudson, F. Johnson, C.A. Peloquin, R.A. Slayden, P.J. Tonge, Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors, *Bioorg. Med. Chem. Lett.* 18 (2008) 3029–3033.
- [61] M.E. Boyne, T.J. Sullivan, C.W. am Ende, H. Lu, V. Gruppo, D. Heaslip, A.G. Amin, D. Chatterjee, A. Lenaerts, P.J. Tonge, R.A. Slayden, Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against *Mycobacterium tuberculosis*: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors, *Antimicrob. Agents Chemother.* 51 (2007) 3562–3567.
- [62] P.J. Tonge, C. Kisker, R.A. Slayden, Development of modern InhA inhibitors to combat drug resistant strains of *Mycobacterium tuberculosis*, *Curr. Top. Med. Chem.* 7 (2007) 489–498.
- [63] X. He, A. Alian, R. Stroud, P.R. Ortiz de Montellano, Pyrrolidine Carboxamides as a Novel Class of Inhibitors of Enoyl Acyl Carrier Protein Reductase from *Mycobacterium tuberculosis*, *J. Med. Chem.* 49 (2006) 6308–6323.
- [64] X. He, A. Alian, P.R. Ortiz de Montellano, Inhibition of the *Mycobacterium tuberculosis* enoyl acyl carrier protein reductase InhA by arylamides, *Bioorg. Med. Chem.* 15 (2007) 6649–6658.
- [65] S. Alcaro, A. Artese, F. Ceccherini-Silberstein, F. Ortuso, C.F. Perno, T. Sing, V. Svicher, Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance, *J. Chem. Inf. Model.* 49 (2009) 1751–1761.

- [66] H.A. Wahab, Y.S. Choong, P. Ibrahim, A. Sadikun, T. Scior, Elucidating isoniazid resistance using molecular modeling, *J. Chem. Inf. Model.* 49 (2009) 97-107.
- [67] A. Ivetac, J.A. McCammon, Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations, *J. Mol. Biol.* 388 (2009) 644-658.
- [68] J.J. Tan, R. Kong, C.X. Wang, W.Z. Chen, Molecular dynamics simulation on the complexes of N-terminal region of HIV-1 gp41 and its C-peptide inhibitors, *Theochem* 682 (2004) 9–15.
- [69] S. Weerasinghe, R. Samantha Dassanayake, Simulation of structural and functional properties of mevalonate diphosphate decarboxylase (MVD), *J. Mol. Model.* 16 (2010) 489-498.
- [70] V. Nukoolkarn, V.S. Lee, M. Malaisree, O. Aruksakulwong, S. Hannongbua, Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors, *J. Theor. Biol.* 254 (2008) 861-786.
- [71] M. Liu, X.J. Cong, P. Li, J.J. Tan, W.Z. Chen, C.X. Wang, Study on the inhibitory mechanism and binding mode of the hydroxycoumarin compound NSC158393 to HIV-1 integrase by molecular modeling, *Biopolymers* 91 (2009) 700-709.
- [72] Y. Zhao, W. Li, J. Zeng, G. Liu, Y. Tang, Insights into the interactions between HIV-1 integrase and human LEDGF/p75 by molecular dynamics simulation and free energy calculation, *Proteins* 72 (2008) 635-645.
- [73] S. Han, Molecular dynamics simulations of thioredoxin with S-glutathiolated cysteine-73, *Biochem. Biophys. Res. Commun.* 362 (2007) 532-537.
- [74] D.A. Rozwarski, C. Vilchèze, M. Sugantino, R. Bittman, J.C. Sacchettini, Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD⁺ and a C16 fatty acyl substrate, *J. Biol. Chem.* 274 (1999) 15582-15589.
- [75] G.M. Morris, D.S. Goodshell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, A.J. Olson, Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function, *J. Comput. Chem.* 19 (1998) 1639-1662.
- [76] D. van der Spoel, E. Lindahl, B. Hess, G. Groenhof, A.E. Mark, H.J.C. Berendsen, GROMACS: fast, flexible and free, *J. Comp. Chem.* 26 (2005) 1701–1719.
- [77] H.J.C. Berendsen, D. van der Spoel, R. van Drunen, GROMACS: a message-passing parallel molecular dynamics implementation, *Comp. Phys. Comm.* 91 (1995) 43–56.

- [78] E. Lindahl, B. Hess, D. van der Spoel, Package for molecular simulation and trajectory analysis, *J. Mol. Mod.* 7 (2001) 306–317.
- [79] W.R.P. Scott, P.H. Hunenberger, I.G. Tironi, A.E. Mark, S.R. Billeter, J. Fennen, A.E. Torda, T. Huber, P. Kruger, W.F. van Gunsteren, The GROMOS biomolecular simulation program package, *J. Phys. Chem. A* 103 (1999) 3596–3607.
- [80] J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, D.A. Case, Development and testing of a general AMBER force field, *J. Comput. Chem.* 25 (2004) 1157–1174.
- [81] H.J.C. Berendsen, J.R. Grigera, T.P. Straatsma, The missing term in effective pair potentials, *J. Phys. Chem.* 91 (1987) 6269–6271.
- [82] B. Hess, H. Bekker, H.J.C. Berendsen, J. Fraaije, LINCS: a linear constraint solver for molecular simulations, *J. Comput. Chem.* 18 (1997) 1463–1472.
- [83] T. Darden, D. York, L. Pedersen, Particle mesh Ewald—an N-Log(N) method for Ewald sums in large systems, *J. Chem. Phys.* 98 (1993) 10089–10092.
- [84] J. Aqvist, C. Medina, J.E. Samuelsson, A new method for predicting binding affinity in computer-aided drug design, *Protein Eng.* 7 (1994) 385–391.
- [85] M.R. Kuo, H.R. Morbidoni, D. Alland, S.F. Sneddon, B.B. Gourlie, M.M. Staveski, M. Leonard, J.S. Gregory, A.D. Janjigian, C. Yee, J.M. Musser, B. Kreiswirth, H. Iwamoto, R. Perozzo, W.R. Jacobs Jr, J.C. Sacchettini, D.A. Fidock, Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data, *J. Biol. Chem.* 278 (2003) 20851–20859.
- [86] World Health Organization, Global tuberculosis report 2013, Available at http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf
- [87] Quemard A, Sacchettini JC, Dessen A, Vilcheze C, Bittman R, Jacobs WR Jr, Blanchard JS (1995) Enzymatic characterization of the target for isoniazid in *Mycobacterium tuberculosis*. *Biochemistry* 34(36):8235–8241
- [88] Rozwarski DA, Vilchèze C, Sugantino M, Bittman R, Sacchettini JC (1999) Crystal structure of the *Mycobacterium tuberculosis* enoyl-ACP reductase, InhA, in complex with NAD⁺ and a C16 fatty acyl substrate. *J Biol Chem* 274(22):15582–15589
- [89] Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK, Carmona S, Carruthers IM, Chan AW, Chen F, Crowther GJ, Doyle MA, Hertz-Fowler C, Hopkins AL, McAllister G, Nwaka S, Overington JP, Pain A, Paolini GV, Pieper U, Ralph SA, Riechers A, Roos DS, Sali A, Shanmugam D, Suzuki T, Van Voorhis WC, Verlinde CL (2008) Genomic-Scale Prioritization of Drug Targets: the TDR Targets Database. *Nat Rev Drug Discov* 7(11):900–907

- [90] Campbell JW, Cronan JE Jr (2001) Bacterial Fatty Acid Biosynthesis: Targets for Antibacterial Drug Discovery. *Annu Rev Microbiol* 55:305-332
- [91] Heath RJ, Rock CO (2004) Fatty acid biosynthesis as a target for novel antibacterials. *Curr Opin Invest Drugs* 5(2):146-153
- [92] White SW, Zheng J, Zhang YM, Rock CO (2005) The structural biology of type II fatty acid biosynthesis. *Annu Rev Biochem* 74:791-831
- [93] Zhang YM, Lu YJ, Rock CO (2004) The reductase steps of the type II fatty acid synthase as antimicrobial targets. *Lipids* 39(11):1055-1060
- [94] Wen L, Chmielowski JN, Bohn KC, Huang JK, Timsina YN, Kodali P, Pathak AK (2009) Functional expression of *Francisella tularensis* FabH and FabI, potential antibacterial targets. *Protein Exp Purif* 65(1):83-91
- [95] Wright HT, Reynolds KA (2007) Antibacterial targets in fatty acid biosynthesis. *Curr Opin Microbiol* 10(5):447-453
- [96] Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr, Sacchettini JC (1998) Modification of the NADH of the isoniazid target (InhA) from *Mycobacterium tuberculosis*. *Science* 279(5347):98-102
- [97] Vilcheze C, Wang F, Arai M, Hazbon MH, Colangeli R, Kremer L, Weisbrod TR, Alland D, Sacchettini JC, Jacobs WR Jr (2006) Transfer of a point mutation in *Mycobacterium tuberculosis* inhA resolves the target of isoniazid. *Nat Med* 12(9):1027-1029
- [98] Dessen A, Quemard A, Blanchard JS, Jacobs WR Jr, Sacchettini JC (1995) Crystal structure and function of the isoniazid target of *Mycobacterium tuberculosis*. *Science* 267(5204):1638-1641
- [99] Johnsson K, Schultz PG (1994) Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from *Mycobacterium tuberculosis*. *J Am Chem Soc* 116(16):7425-7426
- [100] Lei B, Wei CJ, Tu SC (2000) Action mechanism of antitubercular isoniazid. Activation by *Mycobacterium tuberculosis* KatG, isolation, and characterization of inhA inhibitor. *J Biol Chem* 275(4):2520-2526
- [101] Johnsson K, King DS, Schultz PG (1995) Studies on the Mechanism of Action of Isoniazid and Ethionamide in the Chemotherapy of Tuberculosis. *J Am Chem Soc* 117(17):5009-5010
- [102] Zhang Y, Heym B, Allen B, Young D, Cole S (1992) The catalase-peroxidase gene and isoniazid resistance of *Mycobacterium tuberculosis*. *Nature* 358(6387):591-593

- [103] Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR Jr (1994) inhA, a gene encoding a target for isoniazid and ethionamide in *Mycobacterium tuberculosis*. *Science* 263(5144):227-230
- [104] Quemard A, Dessen A, Sugantino M, Jacobs WR Jr, Sacchettini JC, Blanchard JS (1996) Binding of Catalase-Peroxidase-Activated Isoniazid to Wild-Type and Mutant *Mycobacterium tuberculosis* Enoyl-ACP Reductases. *J Am Chem Soc* 118(6):1561-1562
- [105] Saint-Joanis B, Souchon H, Wilming M, Johnsson K, Alzari PM, Cole ST (1999) Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/oxidase, KatG, from *Mycobacterium tuberculosis*. *Biochem J* 338(Pt 3):753-760
- [106] Zhao X, Yu H, Yu S, Wang F, Sacchettini JC, Magliozzo RS (2006) Hydrogen peroxide-mediated isoniazid activation catalyzed by *Mycobacterium tuberculosis* catalase-oxidase (KatG) and its S315T mutant. *Biochemistry* 45(13):4131-4140
- [107] Metcalfe C, Macdonald IK, Murphy EJ, Brown KA, Raven EL, Moody PC (2008) The tuberculosis prodrug isoniazid bound to activating oxidases, *J. Biol. Chem.* 283(10):6193-6200
- [108] Sinha BK (1983) Enzymatic activation of hydrazine derivatives. *J Biol Chem* 258(2):796-801
- [109] Nguyen M, Claparols C, Bernadou J, Meunier B (2001) A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts. *ChemBioChem* 2(12):877-883
- [110] Heym B, Zhang Y, Poulet S, Young D, Cole ST (1993) Characterization of the katG gene encoding a catalase-oxidase required for the isoniazid susceptibility of *Mycobacterium tuberculosis*. *J Bacteriol* 175(13):4255-4259
- [111] Timmins GS, Deretic V (2006) Mechanisms of action of isoniazid. *Mol Microbiol* 62(5):1220-1227
- [112] Johnsson K, Froland WA, Schultz PG (1997) Overexpression, purification, and characterization of the catalase-oxidase KatG from *Mycobacterium tuberculosis*. *J Biol Chem* 272(5):2834-2840
- [113] De La Iglesia AI, Morbidoni HR (2006) Mechanisms of action of and resistance to rifampicin and isoniazid in *Mycobacterium tuberculosis*: new information on old friends. *Rev Argent Microbiol* 38(2):97-109
- [114] Parikh SL, Xiao G, Tonge PJ (2000) Inhibition of InhA, the enoyl reductase from *Mycobacterium tuberculosis*, by triclosan and isoniazid. *Biochemistry* 39(26):7645-7650

- [115] Freundlich JS, Wang F, Vilchère C, Gulten G, Langley R, Schiehser GA, Jacobus DP, Jacobs WR Jr, Sacchetti JC (2009) Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant *Mycobacterium tuberculosis*. *ChemMedChem* 4(2):241-248
- [116] am Ende CW, Knudson SE, Liu N, Childs J, Sullivan TJ, Boyne M, Xu H, Gegina Y, Knudson DL, Johnson F, Peloquin CA, Slayden RA, Tonge PJ (2008) Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. *Bioorg Med Chem Lett* 18(10):3029-3033
- [118] Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA (2007) Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against *Mycobacterium tuberculosis*: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. *Antimicrob Agents Chemother* 51(10):3562-3567
- [119] Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li HJ, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ (2006) High affinity InhA inhibitors with activity against drug-resistant strains of *Mycobacterium tuberculosis*. *ACS Chem Biol* 1(1):43-53
- [120] Luckner SR, Liu N, am Ende CW, Tonge PJ, Kisker C (2010) A slow, tight-binding inhibitor of InhA, the enoyl-ACP reductase from *Mycobacterium tuberculosis*. *J Biol Chem* 285(19):14330-14337
- [121] Pan P (2012) Lead Optimization and Slow-Onset Inhibition of the Enoyl-ACP Reductase (InhA) from *Mycobacterium Tuberculosis*. Ph.D. Diss., Stony Brook University
- [122] Lu XY, Chen YD, Jiang YJ, You QD (2009) Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. *Eur J Med Chem* 44(9):3718-3730
- [123] Kumar A, Siddiqi MI (2008) CoMFA based de novo design of pyrrolidine carboxamides as inhibitors of enoyl acyl carrier protein reductase from *Mycobacterium tuberculosis*. *J Mol Model* 14(10):923-935
- [124] Andrade CH, Salum Lde B, Castilho MS, Pasqualoto KF, Ferreira EI, Andricopulo AD (2008) Fragment-based and classical quantitative structure-activity relationships for a series of hydrazides as antituberculosis agents. *Mol Divers* 12(1):47-59